Indications and uses
For the management of nausea and vomiting, and dizziness associated with motion sickness.
For the management of nausea and vomiting, and dizziness associated with motion sickness.
Motion Sickness The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
Chemically, Meclizine HCl is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.

C25H27ClN2
. 2HCl. H2O M.W. 481.88
Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).
Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
For the management of nausea and vomiting, and dizziness associated with motion sickness.
Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking this drug.
Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.
PREGNANCY, Teratogenic Effects
Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.
Pediatric Use
Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.
Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
Motion Sickness
The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
Meclizine HCI Tablets, USP are available in the following strengths and package sizes:
25 mg (Yellow, oval-shaped, scored, debossed with TL121)
Bottles of 8 NDC 33261--0718-08
Bottles of 10 NDC 33261--0718-10
Bottles of 20 NDC 33261--0718-20
Bottles of 30 NDC 33261--0718-30
Bottles of 60 NDC 33261--0718-60
Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].
Manufactured By:
Jubilant Cadista Pharmaceuticals Inc.
Salisbury, MD 21801, USA.
Repackaged By :
Aidarex Pharmaceuticals LLC,
Corona, CA 92880
Revised 03/11

NDC 33261-0718-30
Meclizine Hydrochloride Tablets, USP
25 mg
Rx only
30 Tablets
Each tablet contains 25 mg of meclizine HCl.
DOSAGE AND USE
See accompanying prescribing information
MOTION SICKNESS:
25 mg to 50 mg daily.
Dispense in tight, light-resistant containers (USP).
Store at 20-25°C (68-77°F)
[See USP Controlled Room temperature].
Jubilant Cadista Pharmaceuticals Inc.
Salisbury, MD 21801, USA
Repackaged By :
Aidarex Pharmaceuticals LLC,
Corona, CA 92880
Rev.# 03/11
Lot No.:
Exp Date:
| Class | Version | Type | Effective |
|---|---|---|---|
| MECLIZINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| ac6963c4-31c6-325f-ee58-83a0a06597ad | Product name | 5 | 20221206 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 33261-718-08 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-fa3f-f424-e053-dadaa90a57ce | MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only |
| 33261-718-10 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-fa3f-f424-e053-dadaa90a57ce | MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only |
| 33261-718-20 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-fa3f-f424-e053-dadaa90a57ce | MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only |
| 33261-718-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-fa3f-f424-e053-dadaa90a57ce | MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only |
| 33261-718-60 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-fa3f-f424-e053-dadaa90a57ce | MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 33261-718-08 | MECLIZINE HYDROCHLORIDE | 8 in 1 BOTTLE, PLASTIC | TABLET | 8 | 1 | |
| 33261-718-10 | MECLIZINE HYDROCHLORIDE | 10 in 1 BOTTLE, PLASTIC | TABLET | 10 | 1 | |
| 33261-718-20 | MECLIZINE HYDROCHLORIDE | 20 in 1 BOTTLE, PLASTIC | TABLET | 20 | 1 | |
| 33261-718-30 | MECLIZINE HYDROCHLORIDE | 30 in 1 BOTTLE, PLASTIC | TABLET | 30 | 1 | |
| 33261-718-60 | MECLIZINE HYDROCHLORIDE | 60 in 1 BOTTLE, PLASTIC | TABLET | 60 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 33261-718-08 | EA - Each | 33261-718 | 4754010b-e034-4fbe-a037-9be67538f3c8 | 1 | 2016-09-02 |
| 33261-718-10 | EA - Each | 33261-718 | e13ef939-c717-4b69-afd1-b280e546aee1 | 1 | 2016-09-02 |
| 33261-718-20 | EA - Each | 33261-718 | 3194e0bb-6c72-40f8-adf0-8f2bab69f14d | 1 | 2015-10-02 |
| 33261-718-30 | EA - Each | 33261-718 | f0a67269-60f1-4821-a0f9-c9f637c20337 | 1 | 2015-10-02 |
| 33261-718-60 | EA - Each | 33261-718 | 86b0cda1-d365-4631-8c63-4fdb43ab32b6 | 1 | 2015-10-02 |
| 59746-121-06 | EA - Each | 59746-121 | 426b1544-2026-4b5e-92b6-b06bf4ad8883 | 1 | 2012-07-24 |
| 59746-121-10 | EA - Each | 59746-121 | ef373495-c09a-4243-9246-5944249609e5 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MECLIZINE HYDROCHLORIDE | ACTIVE INGREDIENT | HDP7W44CIO | 1 | |
| MECLIZINE | ACTIVE MOIETY | 3L5TQ84570 | 1 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| D&C YELLOW NO. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 1 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 33261-718 | 33261-718-08, 33261-718-10, 33261-718-20, 33261-718-30, 33261-718-60 |
| 59746-121 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MECLIZINE HYDROCHLORIDE | HDP7W44CIO | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| D&C YELLOW NO. 10 | 35SW5USQ3G | IACT |
| ALUMINUM OXIDE | LMI26O6933 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | PELLET / ORAL | 1140 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, CHEWABLE / ORAL | 4 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED PELLETS / ORAL | 265 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / BUCCAL | 43 mg | ||
| ALUMINUM OXIDE | ALUMINUM OXIDE | LMI26O6933 | TABLET / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 9.5 %w/v | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 144 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GEL / DENTAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, CHEWABLE / ORAL | 216 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE / ORAL | 280 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE / ORAL | 72 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, DELAYED RELEASE / ORAL | 366 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SYRUP / ORAL | 4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | PELLET / ORAL | 640 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | PELLET / ORAL | 162 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, EXTENDED RELEASE / ORAL | 2575 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, COATED PELLETS / ORAL | 0.01 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED / ORAL | 968 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 47.5 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GUM, CHEWING / ORAL | 2 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CONCENTRATE / ORAL | 0.03 mg/1ml | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, EXTENDED RELEASE / ORAL | 392 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / SUBLINGUAL | 43.2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, FOR SUSPENSION / ORAL | 1875 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED / ORAL | 300 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE / ORAL | 257 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, ORALLY DISINTEGRATING / ORAL | 366 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 616 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, EXTENDED RELEASE / ORAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOLUTION / ORAL | 8 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, DELAYED RELEASE / ORAL | 1 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, ORALLY DISINTEGRATING / ORAL | 184 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040659-001 | MECLIZINE HYDROCHLORIDE | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | |
| A040659-002 | MECLIZINE HYDROCHLORIDE | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 |
| Application-product | TE code |
|---|---|
| A040659-001 | AA |
| A040659-002 | AA |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040659-001 | MECLIZINE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | AA | 2010-06-04 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040659-002 | MECLIZINE HYDROCHLORIDE | 25MG | TABLET / ORAL | AA | 2010-06-04 | 5d02ea3f76ae… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A040659-001 | AA | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A040659-002 | AA | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A040659-001 | AA | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A040659-002 | AA | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A040659-001 | AA | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A040659-002 | AA | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A040659-001 | AA | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A040659-002 | AA | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A040659-001 | AA | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A040659-002 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040659-001 | AA | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040659-002 | AA | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040659-001 | AA | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A040659-002 | AA | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040659-001 | AA | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040659-002 | AA | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040659-001 | AA | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040659-002 | AA | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040659-001 | AA | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040659-002 | AA | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040659-001 | AA | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040659-002 | AA | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040659-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040659-002 | AA | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040659-001 | AA | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040659-002 | AA | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040659-001 | AA | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A040659-002 | AA | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040659-001 | AA | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040659-002 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040659-001 | AA | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040659-002 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040659-001 | AA | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040659-002 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040659-001 | AA | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A040659-002 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040659-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040659-002 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040659-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A040659-002 | AA | 1 | 5d02ea3f76ae… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 3c3b0660-703a-49d4-90ae-8b6a71bc049b | e6a5b78d-1939-4632-ab83-90ca169e56e4 | 2014-01-12 | Warnings, Adverse reactions | 3c3b0660-703a-49d4-90ae-8b6a71bc049b e6a5b78d-1939-4632-ab83-90ca169e56e4 |
Adverse event summaries are temporarily unavailable. Other product information remains available.